Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

SAN DIEGO, July 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 mg and 0.2 mg single doses of APD811. The trial evaluated 32 healthy volunteers in four cohorts of eight participants each – six randomized to APD811 and two to placebo. APD811 was rapidly absorbed and demonstrated dose-proportional pharmacokinetic exposure over the tested dose range. The terminal half-life was approximately 20 hours.

The most frequent treatment-emergent adverse events were headache, vomiting, nausea, jaw pain and flushing. Dose-limiting adverse events of nausea and vomiting occurred at the 0.2 mg dose. As compared to placebo, heart rate trended higher at the 0.05 mg, 0.1 mg and 0.2 mg doses and the corrected QT (QTc) interval trended higher at the 0.1 mg and 0.2 mg doses. Arena believes the QTc observation is not supported by preclinical data and will further evaluate this in future studies. No serious adverse events were reported.

"We are encouraged by the results of this early stage clinical trial that suggest APD811 has the potential for once-daily, oral dosing, and our next step will be to evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a Phase 1b trial," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "The development of APD811 is the result of Arena's continuing commitment to advance our diverse research and development pipeline."

About Pulmonary Arterial Hypertension (PAH)PAH is a progressi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...   MultiVir Inc. ("MultiVir"), a clinical-stage gene ... for the treatment of multiple oncological indications, today announced ... Form S-1 with the U.S. Securities and Exchange Commission ... shares of its common stock. The number of shares ... proposed offering have not yet been determined. MultiVir has ...
(Date:3/30/2015)... , March 30, 2015   CSL ... Agency (EMA) has started the Centralized Procedure for ... its long-acting fusion protein linking recombinant coagulation factor ... approval, rIX-FP will provide hemophilia B patients in ... European Economic Area (EEA) countries, with a long-acting ...
(Date:3/30/2015)... SAN DIEGO , March 30, 2015 ... the appointment of George K. Ng to ... Officer.  In this capacity, Mr. Ng will be responsible ... Mr. Ng joins the Company from BioDelivery Sciences ... General Counsel and a member of senior management that ...
Breaking Medicine Technology:MultiVir Files Registration Statement for Proposed Initial Public Offering 2European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 2European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 3European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 4Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 3
... , NEW YORK, Oct. 13 Reportlinker.com ... is available in its catalogue. , ... Outlook to 2010: Marketing and Sales Strategies ... , http://www.reportlinker.com/p0154807/Reportlinker-Adds-Global-Drug-Manufacturing-Industry-Outlook-to-2010-Marketing-and-Sales-Strategies-and-the-Impact-of-Recession-and-Recovery.html ...
... , PHILADELPHIA, October 13 ... specialty biopharmaceutical company, announces,that it has settled all pending ... New Drug Application ("ANDA") and its,attempt to market generic ... treatment of Attention Deficit Hyperactivity,Disorder. , ...
Cached Medicine Technology:Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 2Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 3Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 4Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 5Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 6Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 7Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 8Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 9Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 10Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 11Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 12Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 13Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 14Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 15Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 16Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 17Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 18Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 19Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 20Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R) 2Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R) 3
(Date:3/30/2015)... 30, 2015 Follow us on ... to develop and establish chronic pain rehabilitation centers are ... the market is poised to benefit from the rise ... the increase in chronic health conditions such as Cancer, ... among others. While conventional treatment for pain management is ...
(Date:3/30/2015)... This report studies the global pharmacovigilance and ... of 2014 to 2019. This market is expected ... 2014 to 2019. , Further Inquiry @ ... pharmacovigilance and drug safety software market has been ... functionality, namely, adverse event reporting software, drug safety ...
(Date:3/30/2015)... March 30, 2015 Tel-Aviv – March ... prescription eyewear, announced the closing of $12.5 million in ... of the Viola Group. The funding will further GlassesUSA's ... leading player in the growing global market of online ... in 2009 by CEO Daniel Rothman, COO Eldad Rothman, ...
(Date:3/30/2015)... 30, 2015 On March 19th, 2015, ... home of the Detroit Lions, LiveToBeSober.org hosted the “Fighting ... pastors, ministers and bishops as well as other civic ... audience at the luncheon, including retired Detroit Lions wide ... Wickstrom and two survivors of their own personal battles ...
(Date:3/30/2015)... New York, New York (PRWEB) March 30, 2015 ... of its Top 10 Exotic Water Awards, with the top ... other winners are listed on the company’s website, along with ... Water’s website, exotic water, glacial water, spring water, mineral water ... Fiji water is one of the top exotic water ...
Breaking Medicine News(10 mins):Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2Health News:Best Exotic Water Brands Acclaimed by 10 Best Water 2
... study conducted by India and Canada which was carried out by ... decrease in the HIV prevalence. The data revealed that women ... of Tamil Nadu, Maharashtra, Karnataka and Andhra Pradesh had fallen from ... mainly seen in the four south Indian states. , ...
... Heart Journal has said that prayers do not seem to ... recently underwent cardiac bypass surgery. // On the contrary, prayers ... that their condition was far worse than thought. ... and the Baptist Memorial Health Care Corp, tracked the progress ...
... yet to receive AIDS medications from government-funded programs, which are ... to buy costly treatments, //according to an annual survey in ... states were also forced to cut down on the medications ... due to a shortage of funds. "The need for HIV-related ...
... babies who were given an aid to help them breathe ... The way was CNEP therapy - continuous negative-extrathoracic pressure. // ... researchers to the original trial in the early 1990s. ... Southall. ,The Nottingham researchers followed up 133 of ...
... Cephalon has been accorded a further six months of ... disorder treatment medication//, Provigil. ,Cephlaon had ... that entailed the provision of clinical studies data after ... ,Cephalon has settled the ‘provogil’patent infringement litigation with ...
... Australia’s crippled mental health services and community-based care centres. ... would triple for Australia's mental health services and hundreds ... the Government accepts the demands of a parliamentary committee. ... patients from institutions into the community. ...
Cached Medicine News:
... Korchek Technologies CareChek Rx ... barcode technology, Windows CE ... integrated scanners (to perform ... the bedside) and an ...
... Safety Infusion System is designed to ensure ... and the right dose. Available in four ... Safety Infusion System allows hospitals to choose ... their needs. DoseGuard™ dose limit technology and ...
... has an installed base of field-proven ... world. Hospital departments using Intermec media ... Supply, Admissions, Nursing Stations, Pharmacy, Medical ... labeling materials includes many products that ...
... Positive Patient Identification™ (PPI) system is an automated solution that identifies the patient, tying all critical information to ... ... ... ...
Medicine Products: